“I’ve experienced no change in my condition, no major deterioration since I started on Esbriet,” said Daniel Castner in an interview with The New York Times. Castner happily added that he’s been free from any treatment side effects, too. Read the top-7 #esbriet articles here: https://wp.me/p56x0V-1kZ Castner, of Napa, California, told Jane…
Pacific Therapeutics Ltd., a clinical stage pharmaceutical company that repurposes and reformulates already approved drugs for larger markets such as cystic fibrosis, recently announced that the United States Patent Office (USPO) has issued United States Patent No. 9029385 for its patent application, “Compositions and Methods for Treating Fibroproliferative Disorders.”…
The Pulmonary Fibrosis Foundation (PFF) recently expressed its sadness over the loss of PFF Ambassador Diane Reichert, who has passed away. Diane received a diagnosis of idiopathic pulmonary fibrosis (IPF) in 2013, after which she became an Ambassador for the Foundation to help assist and raise awareness about her own disease. According to…
The Pulmonary Fibrosis Foundation (PFF) recently announced that registration for PFF Summit 2015: From Bench to Bedside is now open. This is an international conference focused on pulmonary fibrosis (PF), a deadly disease that results from lung scarring. The Summit will address medical education for healthcare professionals, conduct sessions dedicated to those that live with…
Orphan Drug Status was recently granted to an experimental compound, AEOL 10150, under development by Aeolus Pharmaceuticals to address the need for novel treatments for idiopathic pulmonary fibrosis. AEOL 10150 is a broad-spectrum catalytic antioxidant thought to neutralize reactive nitrogen and oxygen species and, consequently, reduce inflammation, oxidative stress and subsequent…
ndd Medical Technologies, a top firm in innovative mobile pulmonary function testing (PFT) that utilizes precise ultrasound mechanisms, recently announced that the company’s EasyOne Pro® was used at a free clinic event held by the San Antonio Pulmonary Fibrosis Support Group. The patients targeted by the clinic were those with…
(Back row, left to right) Broadway Belts for PFF! cast members, Julia Murney, Randy Graff, Julie Halston, Erich Bergen, Zakiya Young, Betsy Wolfe (Front row, left to right) Bobby Creighton, Annaleigh Ashford, Santino Fontana. The Tony award-winning cast performed at the Broadway Belts for PFF! fundraiser to…
Galapagos NV recently announced that GLPG1690, its molecule to address pulmonary diseases such as pulmonary fibrosis, has demonstrated target engagement and a very good safety profile, with Phase 1 results showing favorable drug properties. Galapagos is now advancing GLPG1690 with partner Janssen Pharmaceutica NV. Pulmonary fibrosis…
ProMetic Life Sciences Inc. reported that their investigational PBI-4050 drug, the firm’s leading anti-fibrotic candidate to address idiopathic pulmonary fibrosis (IPF), was approved to begin clinical trials following CTA clearance by Health Canada. IPF is a devastating, chronic and fatal disease that is characterized by a progressive decline in lung function. It is…
The Pulmonary Fibrosis Foundation (PFF), in order to provide top clinical care for those who suffer from Pulmonary Fibrosis (PF), is expanding its PFF Care Center Network (CCN), a patient care concept originally piloted by The University of Chicago’s Pulmonary Clinic. The PFF Care Center…
Get regular updates to your inbox.
